Jefferies' Biogen (NASDAQ: BIIB) analyst Brian Abrahams said they've that a previously-undisclosed Btk inhibitor, BIIB068, geared for lupus, has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE